戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 epatitis, but no deaths were attributable to anti-thymocyte globulin.
2 n, cyclophosphamide, fludarabine, and rabbit anti-thymocyte globulin.
3 ed, consisting of fludarabine, busulfan, and anti-thymocyte globulin.
4 Patients received rabbit-derived intravenous anti-thymocyte globulin 0.5 mg/kg on day -9 and 2 mg/kg
5 4 +/- 0.9 versus 0.2 +/- 0.4, p = 0.011) and anti-thymocyte globulin 0.8 +/- 0.4 versus 0, p = 0.018)
6 dose per day on days -8 to -3), serotherapy (anti-thymocyte globulin [10 mg/kg, one dose per day on d
7  used reduced-intensity conditioning (rabbit anti-thymocyte globulin 4.5 mg/kg in total, cyclophospha
8   Patients were randomly assigned to receive anti-thymocyte globulin 4.5 mg/kg plus standard GVHD pro
9 formation that is not impacted by rituximab, anti-thymocyte globulin (after absorption), or autoantib
10 ulatory drug regimen includes induction with anti-thymocyte globulin and alphaCD20 antibody, followed
11 of a combination of immunomodulatory agents, anti-thymocyte globulin and pegylated granulocyte CSF, n
12 t posttransplant total lymphoid irradiation, anti-thymocyte globulin, and an intravenous donor blood
13 sage, granulocyte colony-stimulating factor, anti-thymocyte globulin, and Solumedrol.
14 ated whether the combination of fludarabine, anti-thymocyte globulin, and total body irradiation (TBI
15  Group previously demonstrated that low-dose anti-thymocyte globulin (ATG) (2.5 mg/kg) preserved beta
16 nsiveness of some patients with trisomy 8 to anti-thymocyte globulin (ATG) and cyclosporine (CsA) wou
17  hypothesized that a combination of low-dose anti-thymocyte globulin (ATG) and pegylated granulocyte
18 ietic stem cell transplantation (AHSCT) with anti-thymocyte globulin (ATG) conditioning as treatment
19                            Pretreatment with anti-thymocyte globulin (ATG) decreases the occurrence o
20                                         High anti-thymocyte globulin (ATG) exposure after HCT has bee
21            The immunosuppressive activity of anti-thymocyte globulin (ATG) has been thought to result
22                                   The use of anti-thymocyte globulin (ATG) has represented the standa
23          However, a clinical significance of anti-thymocyte globulin (ATG) in the female-to-male allo
24 ransplantation); (ii) induction therapy with anti-thymocyte globulin (ATG) instead of anti-interleuki
25                                              Anti-thymocyte globulin (ATG) is a widely used lymphocyt
26                                              Anti-thymocyte globulin (ATG) is used frequently as indu
27 L-18, SCF, IL-6, IL-2, and TNF-a) and active anti-thymocyte globulin (ATG) levels were longitudinally
28 ersial, particularly regarding concerns that anti-thymocyte globulin (ATG) might increase HCV-related
29 disease (GVHD), source of stem cells, use of anti-thymocyte globulin (ATG) or cyclophosphamide in the
30                          Usage and timing of anti-thymocyte globulin (ATG), introduced to the conditi
31                   After preconditioning with anti-thymocyte globulin (ATG), nonlethal total body irra
32 donor antigen alloreactive Treg (darTreg) in anti-thymocyte globulin (ATG)-lymphodepleted, heart-allo
33  34) receiving conditioning with FluMel plus anti-thymocyte globulin (ATG).
34 nsplant total lymphoid irradiation (TLI) and anti-thymocyte globulin (ATG).
35 with cyclophosphamide (200 mg/kg) and equine anti-thymocyte globulin (ATG; 90 mg/kg).
36 hood of cytokine release syndrome (eg, after anti-thymocyte globulin [ATG] therapy).
37 usly (IV) on days -5 and -4; 15 mg/kg equine anti-thymocyte globulin (ATGAM) IV on days -1, +1, and +
38            Immunosuppression included rabbit anti-thymocyte globulin, basiliximab, rituximab, eculizu
39 lter lymphocyte depletion by rhesus-specific anti-thymocyte globulin, but inhibits lymphocyte activat
40 e in vitro generation of regulatory cells by anti-thymocyte globulins could provide ad-ditional thera
41 ased conditioning in combination with rabbit anti-thymocyte globulin, cyclophosphamide, fludarabine a
42                      Induction therapy using anti-thymocyte globulin did not achieve complete T-cell
43 (+) immune reconstitution by individualising anti-thymocyte globulin dose might improve outcomes of a
44                                              Anti-thymocyte globulin dosing was based on bodyweight,
45          We hypothesised that individualised anti-thymocyte globulin dosing would promote CD4(+) immu
46 macaques underwent depletion with polyclonal anti-thymocyte globulin followed by repopulation.
47    All participants were treated with rabbit anti-thymocyte globulin for induction immunosuppression.
48 daveric kidney who received cyclosporine and anti-thymocyte globulin for induction.
49 nds) to investigate individualised dosing of anti-thymocyte globulin for unrelated allogeneic HSCT in
50 e (CES-D) scores were 10.40 (SD 9.88) in the anti-thymocyte globulin group and 14.62 (SD 12.26) in th
51 4 months was 26.3% (95% CI 17.5-35.1) in the anti-thymocyte globulin group and 41.3% (31.3-51.3) in t
52 4 or 5) occurred in 38 (38%) patients in the anti-thymocyte globulin group and in 49 (51%) in the sta
53 TCMR therapy (with high-dose steroids and/or anti-thymocyte globulin): Group 1: Untreated histologic
54 nosis and after treatment with horse-derived anti-thymocyte globulin (hATG), and 6 controls.
55 r T cell depleting therapies, teplizumab and anti-thymocyte globulin, induced only a transient increa
56                            The use of rabbit anti-thymocyte globulin induction (RATG) had a remarkabl
57                 All patients received rabbit anti-thymocyte globulin induction and maintenance immuno
58 sphamide was added to immunosuppression with anti-thymocyte globulin induction, cyclosporine, mycophe
59                              Overexposure to anti-thymocyte globulin leads to poor CD4(+) T-cell immu
60                     Individualised dosing of anti-thymocyte globulin led to a significant improvement
61 ouse heart allograft recipients treated with anti-thymocyte globulin (mATG) critically depends on B c
62                     Using a murine analog of anti-thymocyte globulin (mATG) in a mouse model of cardi
63 art allograft recipients treated with murine anti-thymocyte globulin (mATG).
64 emia received intraportal islet grafts under anti-thymocyte globulin-mycophenolate mofetil-tacrolimus
65 tients; 84% received alemtuzumab (n = 14) or anti-thymocyte globulin (n = 8) as serotherapy.
66 ly assigned 203 eligible patients to receive anti-thymocyte globulin (n=101) or no additional treatme
67 an in 1 patient), fludarabine, thiotepa, and anti-thymocyte globulin or alemtuzumab conditioning were
68 which 44 were treated with pulse steroids or anti-thymocyte globulin, or both.
69 development of BK viremia was induction with anti-thymocyte globulin (P=0.03).
70 roup, with scores of 13.27 (SD 10.94) in the anti-thymocyte globulin plus GVHD prophylaxis group and
71 4 months was 70.6% (95% CI 60.6-78.6) in the anti-thymocyte globulin plus GVHD prophylaxis group comp
72 f relapse was 16.3% (95% CI 8.9-23.7) in the anti-thymocyte globulin plus GVHD prophylaxis group comp
73                           One patient in the anti-thymocyte globulin plus GVHD prophylaxis group died
74     38 (38%) of 99 evaluable patients in the anti-thymocyte globulin plus GVHD prophylaxis group were
75 onth analysis suggest that pretreatment with anti-thymocyte globulin provides clinically meaningful b
76                        All patients received anti-thymocyte globulin (rabbit derived 3 mg/kg per day,
77 complement C3 and C3b inhibition, and rabbit anti-thymocyte globulin (rATG) completely reversed xenog
78                      We reported that rabbit anti-thymocyte globulin (RATG) induction followed by mai
79       The optimal dosing protocol for rabbit anti-thymocyte globulin (rATG) induction in renal transp
80 tuzumab or basiliximab (Bas)/low-dose rabbit anti-thymocyte globulin (rATG), respectively.
81  the induction immunosuppression: (1) Rabbit anti-thymocyte globulin (rATG); (2) Alemtuzumab (C1H); (
82 n of cyclophosphamide (200 mg/kg) and rabbit anti-thymocyte globulin (rATG; 4.5-6.5 mg/kg).
83 nd 100 mg/kg with TBI 2 Gy, fludarabine, and anti-thymocyte globulin results in effective conditionin
84   Standard immunosuppression included rabbit anti-thymocyte globulin-rituximab induction with tacroli
85                                  With rabbit anti-thymocyte globulin-rituximab induction, positive cr
86                                              Anti-thymocyte globulin should be included in the prepar
87 n immunotherapy regimen consisting of rabbit anti-thymocyte globulin (Thymoglobulin) and the monoclon
88                                       Rabbit anti-thymocyte globulin (Thymoglobulin) effectively trea
89 e number of included studies was highest for anti-thymocyte globulin vs. IL-2RA (78 studies), tacroli
90  with busulfan, cyclophosphamide, and rabbit anti-thymocyte globulin was followed by aHSCT.
91                              Rhesus-specific anti-thymocyte globulin was used as induction therapy an
92                        Thymoglobulin (Rabbit Anti-Thymocyte Globulin) was used to treat putative reje
93 To address the limitations of rabbit-derived anti-thymocyte globulin, we generated a recombinant huma
94                             In this trial of anti-thymocyte globulin, we measured treatment-independe
95                                              Anti-thymocyte globulin, which is used in the conditioni
96  three out of four endpoints: tacrolimus and anti-thymocyte globulin with two, and tacrolimus levels,